News

BIO-CAT Grows in Zion Crossroads

BIO-CAT, Inc., a biotechnology company that specializes in enzymes and other advanced microbial solutions, plans to add at least 30,000 square feet to its fermentation facilities in Zion Crossroads. The expansion is projected to start in 2022. The company will add several new jobs and is considering building another 30,000-square-foot section in a second phase.

“Louisa County has partnered with BIO-CAT from the very beginning – they understand not only the economic value that [we bring] to the county, but the overall benefit this expansion can bring to the local community,” said Stephen Schuler, associate vice president of operations.

“It is very rewarding to witness a Louisa business and industry leader grow and thrive locally to meet the demands of their global customers,” said Bob Babyok, Louisa County Board of Supervisors chairman (Green Springs District).

“Similar to brewing and distilling fermentation processes, microbial fermentation can be costly; it requires substantial customization of both building design and equipment. Custom fermentation tanks, stainless steel piping, centrifuges, spray dryers, storage tanks and other unique equipment will be installed at the site, all of which require federal Food and Drug Administration oversight and regular inspections.

“Whether developing beneficial bacteria like probiotics for the human digestive system and production animal feed or developing the right strains to amend the soil microbiome for agriculture, we are developing amazing proprietary solutions for the future,” BIO-CAT Chief Executive Officer and Co-Founder Chris Schuler said.

“BIO-CAT’s financial commitment in this expansion and creation of new job opportunities for our citizens is critical to local economic growth and success,” said Supervisor Fitzgerald Barnes, who represents the Patrick Henry District where the company is located.

BIO-CAT recently celebrated 33 years of industry leadership, during the same year that the company lost its co-founder, Ed Schuler, at the age of 89. Ed, his son Chris and partner Brian Huffman founded the company in 1988.

The firm has doubled its business every five years and is involved in human nutrition, animal nutrition, and crop science. As the company’s revenue has grown, so has its presence in Louisa County. What started as a 12,000-square-foot building has since expanded to over 90,000 square feet.

In 2005, Chris Schuler decided to expand the business portfolio from a pure focus on enzymes, to producing and fermenting probiotics, via an acquisition of a biotech company in Minnesota. After 15 years of success in Minnesota, the company plans to expand that business through the expansion in Zion Crossroads.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by